RxDoctor Payments Data

Manar Al Shahrouri, MD

Pulmonary Disease · Green Bay, WINPI 1093731382

Payments from drug & device makers

What this record shows

This record is dominated by education: $51,198 of the $60,783 with a category attached, or 84.2%. Intuitive Surgical accounts for 99.0% of it on its own, with 5 other manufacturers making up the rest. 2024 is the largest year on record at $44,896, 9.5 times the $4,705 reported in 2022. Among pulmonary disease clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$60,783in general payments, 2019–2025

Across 78 payments — averaging $779.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$60K
  • Abiomed$287
  • Actelion Pharmaceuticals US, Inc.$198
  • Olympus America Inc.$56
  • Grifols USA, LLC$23
  • Covis Pharma GmbH$17

What the payments were for

  • Travel & lodging$6,13510%
  • Food & beverage$3,4506%
  • Education$51,19884%

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,783 in reported general payments places this provider in the 95th percentile of 247 pulmonary disease providers in Wisconsin.

See all pulmonary disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$60,577
Medicare patients
211
Services billed
752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate21$312,234
EsbrietPirfenidone25$261,309
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$79,246
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr74$42,896
Spiriva RespimatTiotropium Bromide25$22,709
Combivent RespimatIpratropium/Albuterol Sulfate27$17,994
Ambrisentan12$15,214
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$14,475
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$12,960
Fluticasone-SalmeterolFluticasone Propion/Salmeterol62$11,745
Breo ElliptaFluticasone/Vilanterol25$9,540
SymbicortBudesonide/Formoterol Fumarate34$9,109
Spiriva HandihalerTiotropium Bromide14$8,076
Arnuity ElliptaFluticasone Furoate18$7,792
Albuterol Sulfate HfaAlbuterol Sulfate74$2,906

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →